Please ensure Javascript is enabled for purposes of website accessibility

Why Opko Health Shares Shriveled by Nearly 8% on Friday

By Eric Volkman – Jul 30, 2021 at 5:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus stock didn't impress with its Q2 results.

What happened

The stock of Opko Health (OPK -2.00%) didn't have its healthiest day on Friday, falling by 7.8% in the wake of the company's latest earnings report.

So what

For its second quarter, Opko Health posted $442.4 million in revenue, nearly 47% higher on a year-over-year basis. That was fueled by volume increases in the company's diagnostic products, which include COVID-19 testing kits (the company's smaller pharmaceutical operations recorded a 22% gain). Largely on the basis of those testing products, however, analysts were collectively expecting nearly $456.4 million on the top line.

A woman seated on a couch, worrying while looking at a thermometer.

Image source: Getty Images.

More discouragingly, the healthcare company flipped into the red on the bottom line with a $16.2 million ($0.03 per share) quarterly loss; the year-ago result was a profit of $33.7 million. The prognosticators were estimating a per-share net profit of $0.02. It should be noted, though, that a share issue linked to convertible notes resulted in a one-time loss of more than $11 million, affecting the bottom-line figure.

Now what

Opko Health's performance led to several price target cuts from analysts. Piper Sandler's Edward Tenthoff reduced his to $5 per share, exactly half of his previous $10, although he maintained his overweight (buy) recommendation. Barrington analyst Michael Petusky shaved his target to $6 from the preceding $8, yet also held his outperform (buy) recommendation.

This might be a bit of an overreaction; Petusky, for one, is basing his move on a slowdown of COVID testing volumes. With the delta variant running roughshod in many locales, that analysis may be premature.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Opko Health Stock Quote
Opko Health
$1.47 (-2.00%) $0.03
Piper Sandler Companies Stock Quote
Piper Sandler Companies
$147.81 (0.49%) $0.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.